CE35 - Maladies infectieuses et environnement

An innovative pipeline to establish the complete Plasmodium vivax life-cycle in the laboratory – VICTOR

Submission summary

Research on P. vivax is greatly lagging behind P. falciparum mainly due to the absence of an efficient laboratory cultivation system on one hand. On the other hand most of the current investigations are compartmentalized, focusing specifically on either individual P. vivax stage (blood stage, liver stage, mosquito stage). As a major breakthrough we propose in the VICTOR project to join forces and expertise for implementing an innovative pipeline establishing the complete Plasmodium vivax life-cycle in the laboratory, independent of transmission seasons and heavy logistic constraints for establishing connections with collection sites located in malaria endemic settings. This platform will provide the today major missing piece of the puzzle to enlarge our general knowledge on P. vivax biology and pave the way for boosting research on P. vivax and promoting the development of potential innovative novel interventions such as new therapeutics and vaccines.

Project coordination

Didier Menard (IP-unité Génétique du Paludisme et Résistance)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

IP-Unité de Génétique fonctionnelle des maladies infectieuses IP-Unité de Génétique fonctionnelle des maladies infectieuses
IP-GPR IP-unité Génétique du Paludisme et Résistance
IPM Institut Pasteur de Madagascar / Immunology of Infectious Diseases
AAU Addis Ababa University
IP-Unité de Biologie des interactions hôte-parasite IP-Unité de Biologie des interactions hôte-parasite

Help of the ANR 334,234 euros
Beginning and duration of the scientific project: September 2021 - 24 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter